BRAF and cancer: Notably, HSP90 is considered a prospective therapeutic target in the treatment of cancers driven by oncoproteins, such as HER2, CDK4, BRAF, EGFR, MET, CRAF, AKT, EML4-ALK, and BCR-ABL [75, 76].